Sangamo Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $14,228 | $581 | $18,306 | $6,437 |
Gross Profit | 14,228 | 581 | 18,306 | 6,437 |
EBITDA | -21,443 | -33,193 | -18,062 | -27,704 |
EBIT | -23,326 | -35,091 | -19,959 | -29,628 |
Net Income | -37,419 | -34,930 | -19,986 | -30,597 |
Net Change In Cash | 14,228 | 581 | 18,306 | 6,437 |
Free Cash Flow | -24,417 | -28,562 | -18,182 | -26,149 |
Cash | 20,948 | 30,528 | 38,344 | 25,180 |
Basic Shares | 337,732 | 304,268 | 256,950 | 220,269 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $39,552 | $57,800 | $176,232 | $111,299 |
Gross Profit | 39,552 | 57,800 | 176,232 | 111,299 |
EBITDA | -100,402 | -89,087 | -96,800 | -180,719 |
EBIT | -108,004 | -98,448 | -118,992 | -201,281 |
Net Income | -122,932 | -97,941 | -257,831 | -192,278 |
Net Change In Cash | 39,552 | 57,800 | 176,232 | 111,299 |
Cost of Revenue | -79,682 | |||
Free Cash Flow | -97,310 | -67,406 | -245,997 | -243,798 |
Cash | 20,948 | 41,918 | 45,204 | 100,444 |
Basic Shares | 280,193 | 201,699 | 174,444 | 154,345 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.11 |
2025-12-31 | -$0.07 |
2025-09-30 | -$0.11 |
2025-06-30 | -$0.08 |
